串联病变中机械取栓与机械取栓联合静脉溶栓的安全性结局对比
本研究为多中心队列汇总的子分析,纳入2015年1月至2020年12月16家卒中中心收治的急性前循环串联病变接受机械取栓的患者。结果显示静脉溶栓联合机械取栓未增加症状性颅内出血、实质血肿2型或出血转化的总体风险,但术中静脉抗血小板治疗与症状性颅内出血风险升高相关,且联合治疗与90天良好功能结局的较高几率相关。
要点
- 静脉溶栓联合机械取栓未增加症状性颅内出血、实质血肿2型或出血转化的总体风险。
- 术中静脉抗血小板治疗的患者中,静脉溶栓与症状性颅内出血风险升高相关(aOR 3.04,95%CI 0.99-9.37,P=0.05)。
- 静脉溶栓联合机械取栓与90天改良Rankin量表评分0-2的较高几率相关(aOR 1.72,95%CI 1.01-2.91,P=0.04)。
核心结论
- 静脉溶栓联合机械取栓治疗串联病变未增加症状性颅内出血、实质血肿2型或总体出血转化的风险,且与所用颈部血管再通技术无关。
- 术中静脉抗血小板治疗可能与非静脉溶栓患者相比增加静脉溶栓患者的症状性颅内出血风险。
- 静脉溶栓联合机械取栓与90天良好功能结局率较高相关。
研究设计与样本
- 本研究为多中心队列汇总的子分析,纳入2015年1月至2020年12月16家卒中中心收治的急性前循环串联病变接受机械取栓的患者。
- 共691例患者,最终纳入512例,其中218例接受静脉溶栓联合机械取栓,294例接受单纯机械取栓。
主要发现
- 调整混杂因素后,静脉溶栓联合机械取栓组与单纯机械取栓组在症状性颅内出血(aOR 1.22,95%CI 0.60-2.51,P=0.583)、实质血肿2型(aOR 0.99,95%CI 0.47-2.08,P=0.985)和出血转化(aOR 0.95,95%CI 0.62-1.46,P=0.817)风险上无差异。
- 在接受静脉抗血小板治疗的患者中,静脉溶栓与症状性颅内出血风险升高相关(aOR 3.04,95%CI 0.99-9.37,P=0.05)。
- 静脉溶栓联合机械取栓组90天改良Rankin量表评分0-2的几率更高(aOR 1.72,95%CI 1.01-2.91,P=0.04)。
- 静脉溶栓联合机械取栓组与单纯机械取栓组在成功再灌注、完全再灌注、90天改良Rankin量表评分0-1、院内死亡或90天死亡风险上无差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to describe the safety and efficacy of mechanical thrombectomy (MT) with or without intravenous thrombolysis (IVT) for patients with tandem lesions and whether using intraprocedural antiplatelet therapy influences MT's safety with IVT treatment. METHODS: This is a subanalysis of a pooled, multicenter cohort of patients with acute anterior circulation tandem lesions treated with MT from 16 stroke centers between January 2015 and December 2020. Primary outcomes included symptomatic intracranial hemorrhage (sICH) and parenchymal hematoma type 2. Additional outcomes included hemorrhagic transformation, successful reperfusion (modified Thrombolysis in Cerebral Infarction score 2b-3), complete reperfusion (modified Thrombolysis in Cerebral Infarction score 3), favorable functional outcome (90-day modified Rankin Scale score 0-2), excellent functional outcome (90-day modified Rankin Scale score 0-1), in-hospital mortality, and 90-day mortality. RESULTS: Of 691 patients, 512 were included (218 underwent IVT+MT and 294 MT alone). There was no difference in the risk of sICH (adjusted odds ratio [aOR], 1.22 [95% CI, 0.60-2.51]; P=0.583), parenchymal hematoma type 2 (aOR, 0.99 [95% CI, 0.47-2.08]; P=0.985), and hemorrhagic transformation (aOR, 0.95 [95% CI, 0.62-1.46]; P=0.817) between the IVT+MT and MT alone groups after adjusting for confounders. Administration of IVT was associated with an increased risk of sICH in patients who received intravenous antiplatelet therapy (aOR, 3.04 [95% CI, 0.99-9.37]; P=0.05). The IVT+MT group had higher odds of a 90-day modified Rankin Scale score 0 to 2 (aOR, 1.72 [95% CI, 1.01-2.91]; P=0.04). The odds of successful reperfusion, complete reperfusion, 90-day modified Rankin Scale score 0 to 1, in-hospital mortality, or 90-day mortality did not differ between the IVT+MT versus MT alone groups. CONCLUSIONS: Our study showed that the combination of IVT with MT for tandem lesions did not increase the overall risk of sICH, parenchymal hematoma type 2, or overall hemorrhagic transformation independently of the cervical revascularization technique used. However, intraprocedural intravenous antiplatelet therapy during acute stent implantation might be associated with an increased risk of sICH in patients who received IVT before MT. Importantly, IVT+MT treatment was associated with a higher rate of favorable functional outcomes at 90 days.
引用
- Rodriguez-Calienes A, Galecio-Castillo M, Farooqui M, et al. Safety Outcomes of Mechanical Thrombectomy Versus Combined Thrombectomy and Intravenous Thrombolysis in Tandem Lesions. Stroke. 2023. PMID: 37602387. doi:10.1161/STROKEAHA.123.042966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。